Desidustat

Zydus Lifesciences plans to acquire commercial assets via M&A or licensing for a specialty portfolio, including potential US launch of liver therapy saroglitazar. The company aims to diversify into medical devices, expand diagnostics and nutrition businesses, and build a specialty play in the US, particularly in orphan and rare diseases. Zydus also targets Europe for M&A, focusing on profitable growth and innovation in unmet medical needs, including orphan and rare diseases. The company is bullish on biologics and globalizing its biosimilars portfolio, with a new facility set to commission in 2025. Zydus received WHO approval for a typhoid conjugate vaccine and expects significant supply orders from UNICEF. The company remains committed to the US market despite potential pricing pressures and political changes.

ICMR partners with Zydus Lifesciences for Phase 2 trials of Desidustat, a HIF-prolyl hydroxylase inhibitor, to treat sickle cell disease. The double-blind, randomized, placebo-controlled study aims to assess efficacy and safety, following DCGI approval.

Zydus Lifesciences and ICMR initiate Phase 2 clinical trials of Desidustat for Sickle Cell Disease, aiming to evaluate efficacy and safety in a double-blind, randomized, placebo-controlled study.

ICMR formalizes MoA with Zydus Lifesciences for phase-2 trials of Desidustat in sickle cell disease patients, aiming to develop innovative, affordable healthcare solutions. Desidustat, invented in India, addresses limitations of current treatments like Hydroxyurea and blood transfusions. The study, co-funded by ICMR, will evaluate Desidustat's efficacy and safety.